

AD-A161 702 CIRCADIAN VARIATION IN HOST DEFENSE(U) MICHIGAN UNIV
ANN ARBOR DEPT OF PHYSIOLOGY M J KLUGER 18 NOV 85
N00014-85-K-0027

AD-A161 702 CIRCADIAN VARIATION IN HOST DEFENSE(U) MICHIGAN UNIV
ANN ARBOR DEPT OF PHYSIOLOGY M J KLUGER 18 NOV 85
N00014-85-K-0027


AD-A161 702 CIRCADIAN VARIATION IN HOST DEFENSE(U) MICHIGAN UNIV 1/1
ANN ARBOR DEPT OF PHYSIOLOGY M J KLUGER 18 NOV 85
N00014-85-K-0027

UNCLASSIFIED F/G 6/15

UNCLASSIFIED F/G 6/15

UNCLASSIFIED F/G 6/15 NL

[illegible][illegible][illegible]



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A

8a. NAME OF FUNDING / SPONSORING ORGANIZATION Office of Naval Research		8b. OFFICE SYMBOL (If applicable) ONR	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER N00014-85-K-0027	
8c. ADDRESS (City, State, and ZIP Code) 800 N. Quincy Street Arlington, VA 22217-5000			10. SOURCE OF FUNDING NUMBERS	
			PROGRAM ELEMENT NO. 61153N	PROJECT NO. RR04108
			TASK NO. NR666043	WORK UNIT ACCESSION NO.
11. TITLE (Include Security Classification) Circadian Variation in Host Defense				
12. PERSONAL AUTHOR(S) Matthew J. Kluger, Ph.D.				
13a. TYPE OF REPORT Annual	13b. TIME COVERED FROM 11/84 TO 10/85		14. DATE OF REPORT (Year, Month, Day) 11/18/85	15. PAGE COUNT 7
16. SUPPLEMENTARY NOTATION NA				
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number) Key words: Interleukin-1, fever, circadian rhythm, body temperature	
FIELD	GROUP	SUB-GROUP		
08				

Figures 2 and 3). Administration of this same dose of sodium salicylate to rats during the morning hours had no effect on body temperature or on activity. Since antipyretic drugs are thought to act by returning an elevated thermoregulatory "set-point" to normal, these data suggest to us that the rise in temperature observed at night in rats is a true fever, perhaps induced by interleukin-1 (IL-1). To eliminate any systemic effects of sodium salicylate, we are currently testing the hypothesis that administration of microgram amounts of sodium salicylate and indomethacin directly into the lateral cerebral ventricles will attenuate the nocturnal rise in body temperature. We are hoping to obtain, within the next few months, antibodies to IL-1 from Dr. John Schmidt of Merck Laboratories. These antibodies will be injected into the central nervous system to determine whether antibodies to IL-1 will also attenuate circadian changes in body temperature.

We also plan to investigate whether a circadian variation in IL-1 exists in human beings. Although claims are made that antipyretic drugs have no effect on the body temperature of afebrile human subjects, to our knowledge, this has never been carefully tested. Permission has been obtained from our Clinical Research Center to study circadian variations in body temperature, trace metals, white blood cell concentrations, and plasma IL-1 concentrations in 10 human subjects. We will determine whether the afternoon rise in body temperature in human subjects can be attenuated by administration of aspirin. Each subject will have his/her body temperature recorded at 10 minute intervals. On day 1 of each experiment, the subject will be given placebos at 4 hour intervals. On day 2 of each experiment, the subject will either be given placebos or aspirin at 4 hour intervals. Blood samples will be taken at 4 hour intervals. The effects of aspirin on body temperature, trace metals, and white cell count will be determined. Plasma concentrations of IL-1 will be determined using the in vitro thymocyte proliferation assay.

Accession No.	NTIS	□	□	□
NTIS	□	□	□	□
Unit	Unit	Unit	Unit	Unit
Justification	Justification	Justification	Justification	Justification
Exempt from	Exempt from	Exempt from	Exempt from	Exempt from
Availability Codes	Availability Codes	Availability Codes	Availability Codes	Availability Codes
Avail and/or Special	Avail and/or Special	Avail and/or Special	Avail and/or Special	Avail and/or Special
Unit	Unit	Unit	Unit	Unit
AA	AA	AA	AA	AA



Objectives

To determine whether interleukin-1 (IL-1), the protein responsible for many of the nonspecific acute phase responses to infection (e.g. fever, leukocytosis, changes in plasma trace metals, etc.), is released on a circadian basis.

1. Accomplishments During the First Year of Support:

Progress during the first year of support has been slower than anticipated largely because about six months elapsed before we could get our temperature and activity telemetry system running adequately to begin collecting data. Our data collection system, the Dataquest III from Mini-Mitter, was the first telemetry system designed by Mini-Mitter for use with an IBM PC. While the use of an IBM dependent system allows for better data acquisition and analysis, the new system had several technical problems, some of which have only recently been corrected.

We plan to test the hypothesis that IL-1 varies on a circadian basis in both human beings and in the laboratory rat. In order to run the human studies a detailed application was prepared and submitted to our Clinical Research Center (CRC) to run these studies. Experiments have been outlined to study circadian variations in body temperature, trace metals, white blood cell concentrations, and IL-1 concentrations in 10 human subjects. We will determine whether the afternoon rise in body temperature in human subjects can be attenuated by administration of aspirin. Each subject will have his/her body temperature recorded on a datalogger (Digistrip II, Kaye Instruments) at 10 minute intervals using thermocouples inserted into the rectum. On day 1 of each experiment, the subject will be given placebos at 4 hour intervals. On day 2 of each experiment, the subject will either be given placebos or aspirin at 4 hour intervals. Blood samples will be taken at 4 hour intervals on both days 1 and 2. The effects of aspirin on body temperature, trace metals, and white cell count will be determined. Plasma concentrations of IL-1 will be determined using the in vitro thymocyte proliferation assay. Prior to testing plasma samples for IL-1 activity, each sample must be gel filtered to remove a large molecular weight inhibitor (Cannon and Dinarello, 1985). Gel columns have been prepared that have been successfully used to separate IL-1 from IL-1 inhibitors and we are now ready to begin these experiments. After consultation with a biostatistician, approval has been granted by our CRC to run these studies.

The animal experiments have involved rats implanted with temperature and activity transmitters. Activity measurement made with the Dataquest System is based upon the principle that as the orientation of the telemetry device (implanted in the rat) changes over the receiver card, the signal strength varies, and hence is picked up as an activity count. We determined the relative hourly activity for each rat by normalizing each hourly activity value to the activity recorded for the hour 11:30 am to 12:30 pm. For example, if the activity value recorded from 2:30 pm to 3:30 pm is 200, and the activity value recorded from 11:30 am to 12:30 pm is 100, then the relative hourly activity from 2:30 to 3:30 pm will be 200/100 or 2.0 (see figure 1).

We have been able to determine the appropriate doses of sodium salicylate that attenuates stress-induced hyperthermia (Singer et al., 1985) and partially attenuates endotoxin-induced fever when these drugs are injected intraperitoneally and intracerebroventricularly. The intraperitoneal administration of an antipyretic dose of sodium salicylate to rats in the late afternoon resulted in significant attenuation of the rise in body temperature normally observed at night; the drug had no effect on activity. These data indicate that the reduction in body temperature cannot be attributed to decreased activity. Administration of this same dose of sodium salicylate to rats during the morning hours had no effect on body temperature, although there were changes in relative activity (see figures 1 and 2). These data will be presented at the FASEB meetings in 1986 (Scales and Kluger, 1986). Experiments are currently in progress to determine whether an intracerebroventricular injection of sodium salicylate and indomethacin (a more potent antipyretic drug) would also block the night-time rise in body temperature. These data suggest to us that the rise in temperature observed at night in rats is a true fever (operationally defined as an elevation in the thermoregulatory set-point), perhaps induced by interleukin-1.

2. Experiments Planned for Year 2:

It is anticipated that the experiments involving circadian variations in body temperature, trace metals, white blood cell counts, and plasma IL-1 concentrations in human subjects will take several months. While these experiments are in progress, we anticipate continuing our animal experimentation. We anticipate completing the studies on the effects of antipyretic drugs injected intraperitoneally and intracerebroventricularly on circadian variation in body temperature. We are also planning to test the hypothesis that the circadian rise in body temperature is a fever by allowing rats to bar press for heat (250 W lamps) in modified Skinner boxes. After rats are trained to press the bar to obtain heat, we will determine whether their preferred environmental temperature (as selected by the rat) increases during the rising phase of their circadian rhythm in body temperature.

Experiments are also planned to determine whether antibodies to IL-1 injected intracerebroventricularly would attenuate the circadian rhythm in body temperature. These studies will be done in collaboration with Dr. John Schmidt of Merck Laboratories (Schmidt et al., 1985). Lastly, we will attempt to determine whether we can detect any circadian changes in plasma and or cerebroventricular concentrations of IL-1. Since many laboratories are working on radioimmunoassays or immunoabsorbant assays for IL-1, presumably more sensitive than the current LAF assay, we may have to wait for the development of these more sensitive assays before a definitive conclusion can be reached regarding circadian variations in IL-1.

References Cited

- Cannon, J.G., and Dinarello, C.A. Increased plasma interleukin-1 activity in women after ovulation. *Science* 227:1247-1249, 1985.
- Kluger, M.J., Singer, R., O'Reilly, B.C., and Scales, W.E. Selection of cage size by Sprague-Dawley rats. Submitted for publication.
- Scales, W.E., and Kluger, M.J. Sodium salicylate attenuates circadian rise in body temperature in the rat. *Fed. Proc.*, In press, 1986
- Schmidt, J.A., Limjuco, G., Cameron, P., Bayne, E., Rupp, E., Bennett, C., Rodkey, J., Shapiro, J., Boger, J., and Tocci, M. Molecular biology of the major charged species of normal human interleukin-1 and development of specific antibody probes. *J. Leukocyte Biology*. 37(6):740, 1985.
- Singer, R., Harker, C.T., Vander, A.J., and Kluger, M.J. Hyperthermia induced by open-field is blocked by salicylate. *Physiol. and Behavior*, In Press, 1985.




Figure 1. Relative activity of 10 rats. The rats were on a 12:12 light:dark photoperiod; the horizontal bar represents the period of darkness. Each data point represents the mean \pm 1 S.E.




Figure 2. Effect of intraperitoneal injection of 1 ml of 0.9% sodium chloride (SA) or 300 mg/kg sodium salicylate (SS) in 10 rats on the change in body temperature over a 3 hr period following the injection. The injections were given either at 5 PM (during the time of day when body temperature is generally rising) or at 9:30 AM (during the time of day when body temperature is generally low and stable). Comparisons were made between body temperatures on the day of injection and body temperatures on the following day. Only an injection of sodium salicylate in the PM resulted in a significant change in body temperature.




Figure 3. Effect of intraperitoneal injection of 1 ml of 0.9% sodium chloride (SA) or 300 mg/kg sodium salicylate (SS) in 10 rats on relative change in activity. The injections were given either at 5 PM (during the time of day when body temperature is generally rising) or at 9:30 AM (during the time of day when body temperature is generally low and stable). Comparisons were between relative activity on day 1 and the relative activity on day 2 (the day following injection), expressed as a ratio. A value of 1.0 indicates no change in activity; values less than 1.0 indicate greater activity on the day of injection; values greater than 1.0 indicate less activity on the day of injection. These data indicate that although body temperature fell when SS was injected at 5 PM, this was not accompanied by a change in activity. Although an injection of SS at 9:30 AM resulted in an increase in relative activity, this did not result in a change in body temperature. Similarly, although an injection of SA in the AM resulted in a decrease in relative activity, this was not accompanied by any change in body temperature.

DISTRIBUTION LIST

Immunological Defense Program

Annual, Final and Technical Reports (one copy each except as noted)

Dr. John D. Clements
Department of Microbiology
and Immunology
Tulane University
1430 Tulane Avenue
New Orleans, LA 70112

Francis A. Ennis, M.D.
Department of Medicine
University of Massachusetts
Medical School
55 Lake Avenue
Worcester, MA 01605

Dr. Edward A. Havell
Trudeau Institute
P.O. Box 59
Saranac Lake, NY 12983

Dr. Arthur G. Johnson
Department of Medical
Microbiology and Immunology
University of Minnesota
School of Medicine
2205 East 5th Street
Duluth, MN 55812

Dr. Matthew J. Kluger
Department of Physiology
University of Michigan Med. School
7620 Medical Science II Building
Ann Arbor, MI 48109

Dr. Roger M. Loria
Department of Microbiology
and Immunology
Virginia Commonwealth University
Box 678, MCV Station
Richmond, VA 23298-0001

Dr. Ernest D. Marquez
Bioassay Systems Corporation
225 Wildwood Avenue
Woburn, MA 01801

Dr. Robert I. Mishell
Department of Microbiology
and Immunology
University of California, Berkeley
Berkeley, CA 94720

James J. Mond, M.D.
Department of Medicine
Uniformed Services University
of the Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20814

Dr. Page S. Morahan
Department of Microbiology
Medical College of Pennsylvania
3300 Henry Avenue
Philadelphia, PA 19129

David A. Stevens, M.D.
Department of Medicine
Santa Clara Valley Medical Center
Stanford University
751 S. Bascom Avenue
San Jose, CA 95128

Dr. Barnet M. Sultzter
Department of Microbiology
and Immunology
Downstate Medical Center
450 Clarkson Avenue

G. Jeanette Thorbecke, M.D.
Department of Pathology
New York University
School of Medicine
550 First Avenue
New York, NY 10016

Dr. Alvin L. Winters
Department of Microbiology
University of Alabama
University, AL 35486

Annual, Final and Technical Reports (one copy each except as noted)

Dr. Jeannine A. Majde, Code 441CB
Scientific Officer, Immunology Program
Office of Naval Research
800 N. Quincy Street
Arlington, VA 22217

Administrator (2 copies) (Enclose DTIC Form 50)
Defense Technical Information Center
Building 5, Cameron Station
Alexandria, VA 22314

Annual and Final Reports Only (one copy each)

Commanding Officer
Naval Medical Command
Washington, DC 20372

Commanding Officer
Naval Medical Research & Development Command
National Naval Medical Center
Bethesda, MD 20814

Director, Infectious Diseases Program Center
Naval Medical Research Institute
National Naval Medical Center
Bethesda, MD 20814

Commander
Chemical and Biological Sciences Division
Army Research Office, P.O. Box 12211
Research Triangle Park, NC 27709

Commander
U.S. Army Research and Development Command
Attn: SGRD-PLA
Fort Detrick
Frederick, MD 21701

Commander
USAMRIID
Fort Detrick
Frederick, MD 21701

Directorate of Life Sciences
Air Force Office of Scientific Research
Bolling Air Force Base
Washington, DC 20332

Administrative Contracting Officer
ONR Resident Representative
(address varies - obtain from Business Office)

Final and Technical Reports Only

Director, Naval Research Laboratory (6 copies)
Attn: Technical Information Division, Code 2627
Washington, DC 20375

END

FILMED

1-86

DTIC